Li CG, Zhou ZP, Jia YZ, Tan XL, Song YY. Radioactive 125I seed implantation for locally advanced pancreatic cancer: A retrospective analysis of 50 cases. World J Clin Cases 2020; 8(17): 3743-3750 [PMID: 32953850 DOI: 10.12998/wjcc.v8.i17.3743]
Corresponding Author of This Article
Cheng-Gang Li, MD, PhD, Associate Professor, Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China. lcgang301@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 6, 2020; 8(17): 3743-3750 Published online Sep 6, 2020. doi: 10.12998/wjcc.v8.i17.3743
Radioactive 125I seed implantation for locally advanced pancreatic cancer: A retrospective analysis of 50 cases
Cheng-Gang Li, Zhi-Peng Zhou, Yu-Ze Jia, Xiang-Long Tan, Yu-Yao Song
Cheng-Gang Li, Zhi-Peng Zhou, Yu-Ze Jia, Xiang-Long Tan, Yu-Yao Song, Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, China
Author contributions: Li CG and Zhou ZP contributed equally to this work and should be considered as co-first authors; Li CG and Zhou ZP analyzed and interpreted the data and wrote the article; Tan XL, Jia YZ, and Song YY drafted the work and collected the data; Li CG designed the study and revised the manuscript for important intellectual content.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Chinese PLA General Hospital (S2016-098-02).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All authors declare no conflicts of interest related to this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Cheng-Gang Li, MD, PhD, Associate Professor, Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China. lcgang301@126.com
Received: April 14, 2020 Peer-review started: April 14, 2020 First decision: May 15, 2020 Revised: May 25, 2020 Accepted: August 12, 2020 Article in press: August 12, 2020 Published online: September 6, 2020
ARTICLE HIGHLIGHTS
Research background
Pancreatic cancer has the characteristics of late detection, early metastasis, rapid progression, and poor prognosis.
Research motivation
Application of 125I seeds in the treatment of pancreatic cancer.
Research objectives
To summarize a single center experience with 125I seed implantation in the treatment of locally advanced pancreatic cancer.
Research methods
The demographics and perioperative outcomes of a consecutive series of patients who underwent 125I seed implantation to treat locally advanced pancreatic cancer were retrospectively analyzed. According to the results of preoperative computed tomography or magnetic resonance imaging, the treatment planning system was used to determine the area and number of 125I seeds implanted.
Research results
Among the 50 patients, there were 29 males and 21 females, with a mean age of 56.9 ± 9.8 years. The main reason for the failure of radical resection was superior mesenteric artery invasion, followed by superior mesenteric vein invasion. Twenty-one patients underwent palliative surgery and postoperative pain relief occurred in 40 patients. The estimated blood loss in operation was 107.4 ± 115.3 mL and none of the patient received blood transfusion. After operation, 26 patients received chemotherapy and 24 patients did not. The 1-year survival rate was significantly higher in patients who received chemotherapy than in those who did not. The mean OS of patients of the chemotherapy group and non-chemotherapy group was 14 mo and 11 mo, respectively.
Research conclusions
Our experience shows that 125I seed implantation is not only effective for unresectable local advanced pancreatic cancer patients, but can also reduce the clinical symptoms and prolong the relative survival time of those patients.
Research perspectives
The diversification of cancer treatments has contributed to its survival rate.
